EMILIO CLEMENTI- BIOGRAPHICAL SKETCH

SNAPSHOT		
Full Professor of Pharmacology, University of Milano, School of Medicine, Milan, Italy		
• Director, Clinical Pharmacology Unit, L. Sacco Hospital (NHS), Milan, Italy		
Coordinator, Pharmacogenetics section, Italian Society of Pharmacology		
• Over 20 years of experience of research in basic, translational and clinical pharmacology		
Editor in Chief, Pharmacological Research, Elsevier.		
PROFESSIONAL EXPERIENCE		
2008-present	L. Sacco Hospital (National Health System) (Milan, Italy)	
	Director Clinical Pharmacology Unit (since 2021 comprising the International Centre for Pesticide Safety and since 2023 the Clinical Research Service of the Hospital)	
	 Strategic planning and coordination of clinical activity in therapeutic drug monitoring for the National Health System including pharmacovigilance monitoring projects sponsored by the Italian medicines Agency 	
	 Development of a clinical centre for pharmacogenetics and therapy optimisation 	
	 Strategic planning for a centre devoted to ecotoxicology/ environmental science food 	
	safety, environmental chemistry, and management and processing of health data	
2005-present	University of Milano (Milan, Italy)	
-	Full Professor of Pharmacology	
	• Teaching of Pharmacology (general and clinical), the School of Medicine and Surgery	
	Teaching in Continuing Medical Education courses of pharmacology	
	Research in pharmacovigilance, therapeutic drug monitoring, pharmacogenetics.	
	• Research in translational pharmacology on metabolism with a focus on experimental	
	therapies for Muscular Dystrophies	
2003-present	E. Medea Clinical Research Institute (Lecco, Italy)	
-	Coordination of the pharmacology sector	
	Research on drug therapies in paediatric neuro-rheabilitation	
1999-2005	University of Calabria (Cosenza, Italy)	
	Associate Professor of Pharmacology	
	• Teaching of Pharmacology (general and clinical), the School of Pharmacy	
	Teaching in Continuing Medical Education courses of pharmacology	
	• Research in basic pharmacology in the field of signal transduction (sphingolipid	
	metabolism and Nitric Oxide-dependent pathways).	
1999-2005	San Raffaele Clinical Research Institute (Milan, Italy)	
	Head of the Cellular Pharmacology Unit	
	Research in basic/translational pharmacology in molecular mechanisms of muscular	
	degeneration	
	Supervisor, PhD Programme, Open University (San Raffaele site)	
1997-1999	University College London (London, UK)	
	Marie Curie Research Fellow	
	Research on nitric oxide role in cell metabolism and bioenergetics	
1992-1996	University Magna Graecia (Catanzaro, Italy)	
	Reader of Pharmacology	
	• Research in basic pharmacology in the field of signal transduction (sphingolipid	
MEMORENCE	incrabolishi and calcium-dependent pathways	
MEMBERSHIPS	Mombor the National Ethics Desiliation Compatitud	
2022-present	Councillor the Italian Society of Dharmagelory	
2022-present	Executive Committee member. International Union of Basic & Clinical Dharmacology	
2010-present	IIIPHAR	
	1.01.1	

2017-2019	Councillor- The European Association of Clinical Pharmacology and Therapeutics
2015-2023	Member, the Ethics Committee of the "Fondazione Ospedale Maggiore" Scientific
	Institute, Milan
2015-2019	National delegate- The European Association of Clinical Pharmacology and Therapeutics
2013-present	Councillor clinical section, the Italian Society of Pharmacology
2009-2013	Councillor the Italian Society of Pharmacology
EDUCATION/TRAINING	
1972-1983	Conservatory of Music G.Verdi- M. Mus, piano with full marks
1977-1982	Classic Licaeum G. Carducci- Bachelor in Humanities with full marks
1982-1988	University of Milan- M.D. degree with honours
1984-1988	Conservatory of Music G.Verdi - specialisation in harpsichord playing and baroque music
1990-1993	University of Brescia - PhD in Experimental Pharmacotherapy
FUNDING	
	Over the years he has attracted more than 5 million euros for his research group from Italian
	charities (Telethon, The Italian Association for Cancer Research), the Ministry of research,
	the Ministry of health, the Italian medicines Agency, and the EU
	Funding for research in 2021-2022
	Ministry of Research PRIN Grant € 380000 and NextGenerationEU € 350000
	Ministry of Health Piano Operativo Salute (Operational Health Plan) € 1000000

Scientific Resumé

Author of more than 400 articles in basic translational and clinical pharmacology with more than 20000 citations; H index: 60 (all from Scopus)

https://www.scopus.com/authid/detail.uri?authorId=7101959716 https://orcid.org/0000-0001-7333-8270

I started by working on calcium and sphingolipid metabolism signalling, helping to identify the type 3 ryanodine receptor, to then introduce nitric oxide as regulator of these pathways; this led me to investigate the role of nitric oxide in mitochondrial bioenergetics, a work done at UCL, and then contribute to identify nitric oxide role in mitochondrial biogenesis and the control of cell metabolism. The relevance of this in therapeutic perspective led me to investigate the role of nitric oxide in the pathophysiology of skeletal muscle and as a therapeutic in Duchenne Muscular Dystrophy with studies moving from basic to translational research and finally to a phase I and a phase I/II clinical study. The advantage of being director since 2005 of a Clinical Pharmacology Unit allowed me to deepen my study on metabolism by addressing metabolic adverse drug reactions, in particular the ones associated with the use of antipsychotic drugs in paediatric patients, through approaches that combined basic research with pharmacokinetic, pharmacogenetic and pharmacoepidemiological analyses.

Ten relevant publications

- Expression of a ryanodine receptor-Ca2+ channel that is regulated by TGF-beta G Giannini, E Clementi, R Ceci, G Marziali, V Sorrentino Science - 1992 Jul 3; 257(5066):91-4. doi: 10.1126/science.1320290.
- Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione E Clementi, G C Brown, M Feelisch, S Moncada Proc Natl Acad Sci U S A - 1998 Jun 23; 95(13):7631-6. doi: 10.1073/pnas.95.13.7631.
- Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide E Nisoli, E Clementi, C Paolucci, V Cozzi, C Tonello, C Sciorati, R Bracale, A Valerio, M Francolini, S Moncada, MO Carruba Science - 2003 Feb 7; 299(5608):896-9. doi: 10.1126/science.1079368.
- Mitochondrial biogenesis by NO yields functionally active mitochondria in mammals E Nisoli, S Falcone, C Tonello, V Cozzi, L Palomba, M Fiorani, A Pisconti, S Brunelli, A Cardile, M Francolini, O Cantoni, MO Carruba, S Moncada, E Clementi Proc Natl Acad Sci U S A - 2004 Nov 23; 101(47):16507-12. doi: 10.1073/pnas.0405432101.
- Calorie restriction promotes mitochondrial biogenesis by inducing the expression of eNOSE Nisoli, C Tonello, A Cardile, V Cozzi, R Bracale, L Tedesco, S Falcone, A Valerio, O Cantoni, E Clementi, S Moncada, MO Carruba Science - 2005 Oct 14; 310(5746):314-7. doi: 10.1126/science.1117728.
- 6. Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapyS Brunelli, C Sciorati, G D'Antona, A Innocenzi, D Covarello, BG Galvez, C Perrotta, A Monopoli, FSanvito, R Bottinelli, E Ongini, G Cossu, E Clementi Proc Natl Acad Sci U S A 2007 Jan 2; 104(1):264-9. doi: 10.1073/pnas.0608277104.
- Nitric oxide inhibition of Drp1-mediated mitochondrial fission is critical for myogenic differentiationC De Palma, S Falcone, S Pisoni, S Cipolat, C Panzeri, S Pambianco, A Pisconti, R Allevi, M T Bassi, G Cossu, T Pozzan, S Moncada, L Scorrano, S Brunelli, E Clementi Cell Death Differ - 2010 Nov; 17(11):1684-96. doi: 10.1038/cdd.2010.48..
- Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients MG D'Angelo, S Gandossini, F Martinelli Boneschi, C Sciorati, S Bonato, E Brighina, G Comi, AC Turconi, F Magri, G Stefanoni, S Brunelli, N Bresolin, D Cattaneo, E Clementi Pharmacol Res - 2012 Apr; 65(4):472-9. doi: 10.1016/j.phrs.2012.01.006.
- 9. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: an observational study in real-life settings M Pozzi, D Cattaneo, S Baldelli, S Fucile, A Capuano, C Bravaccio, L Sportiello, S Bertella, F Auricchio, R Bernardini, C Ferrajolo, G Guastella, E Mani, Carla Carnovale, Simone Pisano, Concetta Rafaniello, Maria Pia Riccio, Renata Rizzo, Maria Grazia Scuderi, Serena Sperandeo, Laura Villa, Antonio Pascotto, Massimo Molteni, Francesco Rossi, Sonia Radice, Emilio Clementi Eur J Clin Pharmacol 2016 Mar; 72(3):285-93. doi: 10.1007/s00228-015-1982-0.
- Autophagy controls neonatal myogenesis by regulating the GH-IGF1 system through a NFE2L2and DDIT3-mediated mechanismS Zecchini , M Giovarelli , C Perrotta, F Morisi , T Touvier, I Di Renzo, C Moscheni, MT Bassi, D Cervia, M Sandri, E Clementi, C De Palma Autophagy -2019 Jan; 15(1):58-77. doi: 10.1080/15548627.2018.1507439.